studies conducted prior to the use of thrombolytics suggests that anticoagulation decreases the incidence of LV thrombus formation by 68% (3). Furthermore, the risk of ischemic stroke is higher following acute MI, with an incidence of about 1.5% to 3.6% (3,9). This risk is greatest in the first month and is also more common in patients with anterior infarctions and lower ejection fractions (9-11). Importantly, anticoagulation has been shown to reduce the incidence of stroke and mortality after acute MI in randomized studies from the pre-thrombolytic era (12,13).
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However, not all studies find a link among anterior MI, LV thrombus, and embolic events. In the thrombolytic era, the low molecular weight heparin dalteparin reduced LV thrombus formation by 37% in 517 randomized patients after anterior acute MI. However, this therapy had no impact on early thromboembolic events (14) . Similar findings were echoed in a larger observational study of 2,949 patients, in which anticoagulation failed to reduce the incidence of In conclusion, the current study by Le May et al. 
